Abstract
The ADAM (a disintegrin and metalloprotease) family of proteins possess multi-domain structures composed of a signal peptide, a prodomain, a metalloprotease domain, a disintegrin-like domain, a cysteine rich domain, an epidermal growth factor-like domain, a transmembrane domain and cytoplasmic tail. The disintegrin-like domain shares sequence similarity with the soluble venom disintegrins, a family of proteins which are potent inhibitors of integrinmediated platelet aggregation and cell adhesion. Several ADAMs have been reported to interact with integrins, and the disintegrin-like domain may be crucial part in this respect. A description of structure-activity relationship of ADAM proteins interacting with integrin is outlined in this review. The review highlights recent reports on potential integrin family for ADAMs and how ADAMs selectively modulate interaction for integrin mediated cell function. Lastly, it describes progress in understanding the structural features and functional roles of the ADAMs in normal and pathological conditions and how this insight may assist the development of new therapeutic approaches.
Keywords: ADAM-15, RGD-disintegrin domain, metalloprotease domain, EGF-like domains, cytosolic portion
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Structure-Activity Relationship Studies on ADAM Protein-Integrin Interactions
Volume: 5 Issue: 1
Author(s): X. Lu, D. Lu, M. F. Scully and V. V. Kakkar
Affiliation:
Keywords: ADAM-15, RGD-disintegrin domain, metalloprotease domain, EGF-like domains, cytosolic portion
Abstract: The ADAM (a disintegrin and metalloprotease) family of proteins possess multi-domain structures composed of a signal peptide, a prodomain, a metalloprotease domain, a disintegrin-like domain, a cysteine rich domain, an epidermal growth factor-like domain, a transmembrane domain and cytoplasmic tail. The disintegrin-like domain shares sequence similarity with the soluble venom disintegrins, a family of proteins which are potent inhibitors of integrinmediated platelet aggregation and cell adhesion. Several ADAMs have been reported to interact with integrins, and the disintegrin-like domain may be crucial part in this respect. A description of structure-activity relationship of ADAM proteins interacting with integrin is outlined in this review. The review highlights recent reports on potential integrin family for ADAMs and how ADAMs selectively modulate interaction for integrin mediated cell function. Lastly, it describes progress in understanding the structural features and functional roles of the ADAMs in normal and pathological conditions and how this insight may assist the development of new therapeutic approaches.
Export Options
About this article
Cite this article as:
Lu X., Lu D., Scully F. M. and Kakkar V. V., Structure-Activity Relationship Studies on ADAM Protein-Integrin Interactions, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (1) . https://dx.doi.org/10.2174/187152507779315822
DOI https://dx.doi.org/10.2174/187152507779315822 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets
Current Cancer Drug Targets New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention
Current Pharmaceutical Design The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry Cell Arrest and Apoptosis Induced by the Next Generation of Vanadium Based Drugs: Action Mechanism to Structure Relation and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Chemoprotection and Selection by Chemotherapy of Multidrug Resistance-associated Protein-1 (MRP1) Transduced Cells
Current Gene Therapy Oxazolidinones as Chiral Auxiliaries in the Asymmetric 1,4-Conjugate Addition Reaction Applied to the Total Synthesis of Natural Products: A Supplemental Mini-Review
Current Organic Synthesis Peptides for Therapy and Diagnosis of Alzheimer's Disease
Current Pharmaceutical Design <sup>11</sup>C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications
Current Radiopharmaceuticals Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery The Cellular Protective Effects of Rosmarinic Acid: From Bench to Bedside
Current Neurovascular Research Nitric Oxide is a Signaling Molecule in Spermatozoa
Current Pharmaceutical Design